type II RAF dimer kinase inhibitor

oral 450 mg BID, Ph. II in BRAF/RAS cancers

demonstrated activity in NRAS-mut. tumors

Nature, May 5, 2021

Genentech, CA / Hanmi Pharma, KR

Belvarafenib

The Hanmi/Genentech type II RAF kinase inhibitor, belvarafenib, is a potent and selective inhibitor of RAF dimers. GNE-9815 was covered last month, which was used to validate the biology supporting clinical…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: